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Microenvironmental cues in cancer stemness
Intra-tumour heterogeneity manifests both at the level of mutational burden, and at a functional level within genetically homogenous populations. A new modelling approach suggests stemness within colorectal tumours is defined by microenvironmental cues secreted from cancer-associated fibroblasts rather than cell-intrinsic properties.
D. J. Flanagan, M. C. Hodder and O. J. Sansom I t is well accepted that tumours display extensive cellular and molecular heterogeneity, making it cumbersome to identify cancer stem cells (CSCs) that sustain tumour growth 1, 2 . Adult stem cells and CSCs often share molecular and growth features, which has permitted better characterisation of CSCs in multiple malignancies 3 
. Previous studies have adopted an Lgr5
+ stem-cellcentric model to describe the growth dynamics of colorectal cancer (CRC) 4, 5 , and have demonstrated that intestinal adenomas retain cellular hierarchy 6, 7 . Furthermore, several studies have postulated the potential utility in targeting Lgr5 + CSCs in CRC patients 8, 9 . In this issue of Nature Cell Biology, Lenos et al. 10 take an unbiased approach to model growth of colorectal tumours and determine that markers of stem cells, such as Lgr5, and stemness are not one and the same. The authors further define that the tumour microenvironment is able to dictate stemness in CRC models and that tumours grow from the edge rather than by ubiquitous expansion of the tumour bulk.
Through the combination of mouse models and organoid xenografts, targeted ablation of Lgr5 + cells in CRC has been shown to be sufficient to perturb tumour growth 4, 5 . However, following cessation of Lgr5 + cell depletion, tumour expansion is immediately reinstated, revealing Lgr5 + cells as a major contributor to tumour growth and demonstrates the impressive plasticity within CRC. The latter phenomenon indicates that, in addition to cell intrinsic mutational burden, cell extrinsic cues dictate tumour cell fate and stemness. The findings in the current study indicate that cells positive for 'stem cell markers' take a back seat, and instead the environmental cues provided by surrounding stromal cells confer stemness and drive tumour growth.
Lenos et al. use a marker-free tamoxifen inducible labelling system to stochastically label tumour cells in mouse xenograft models, employing both a traditional two-dimensional cell line and two patientderived spheroid lines. The sizes of individual labelled clones were evaluated at various time points post induction, and the distributions of clone sizes over time were integrated into a stochastic model of tumour growth. This model was designed to infer whether tumour growth is inherently driven by cells at the extreme of an intrinsic hierarchical structure, consistent with a CSC-centric model, or dictated by extrinsic factors, consistent with a microenvironmental-niche model.
These data indicated that all tumour lines, when implanted subcutaneously into mice, did not contain evidence of an intrinsic hierarchical organisation, and thus clonal out-growth was defined by environmental factors rather than cellintrinsic factors. The authors continued by approximating a cellular division rate of between 0.15 and 0.35 effective divisions per day for clonogenic cells, and defining that the vast majority (> 98%) of all clonogenic cells were housed toward the edges of the tumour. This fundamental growth dynamic of CRC was mimicked by orthotopic implantation of xenografts into the caecum, indicating that the subcutaneous microenvironment is not driving a unique growth dynamic of CRC xenografts.
In these models, the majority of proliferative cells (marked by Ki67) were located in the outermost 300 μ m of the tumour; a feature that the authors demonstrated was consistent with that of primary human CRC. This characteristic tumour proliferation at a holistic level, is consistent with a model of surface tumour growth, and accurately predicted the rate of macroscopic tumour expansion. The authors conclude that CRC grows from surface expansion while the central bulk of the tumour contributes little to tumour growth ( Fig. 1) , which is supported by another recent publication in Nature Communications 11 . It has previously been reported that environmental cues are able to dictate CRC cell fate in xenograft models 12 . The authors employed an innovative enzymatic digestion technique to separate the outermost areas of the tumour bulk from the core region. RNA sequencing comparing the two populations revealed, as expected, an enrichment for genes associated with proliferation at the tumour edge. Notably, no enrichment for stem cell signatures or difference in the proportion of Lgr5 + cells was detected in either population, and this was confirmed by RNA in situ hybridization and immunohistochemistry for stem cell markers. These data highlight the discrepancy between CSC marker expression and functionality.
The importance of the microenvironment was again highlighted by complete plasticity within the tumour bulk. Following enzymatic digestion, the authors transplanted the tumour centre back into mice and observed a rapid reinstatement of surface growth features. Furthermore, the centre tumour cells were functionally indistinguishable from the edge cells when compared using an in vitro clonogenicity assay. Thus, when the environmental cues are identical, tumour cell plasticity enables a proliferative state regardless of their origin. It appears that conclusions cannot be drawn between clonogenicity assays and contribution towards tumour growth rates. The authors demonstrated that time to tumour establishment (tumour volume > 100 mm 3 ) correlates with the measured clonogenicity of a cell population, where as expansion following tumour establishment does not.
A correlation between Ki67 + tumour cells and the distance to the nearest cancerassociated fibroblast (CAF) was observed, which prompted Lenos et al. to investigate the functional significance of CAFs for tumour growth dynamics. To test this, co-cultures were established that revealed increased epithelial cell growth when cultured with CAFs. These findings were corroborated using conditioned medium from CAFs, indicating the importance of CAF-secreted factors in regulating epithelial cell growth. To identify factors that may influence tumour growth distribution, the authors interrogated their RNA sequencing and identified osteopontin (OPN) as the most highly expressed secreted factor in CAFs. Levels of OPN have previously been shown to be increased in solid malignancies, including CRC 13, 14 . Clonal analysis of OPN-overexpressing tumour cells after subcutaneous implantation revealed that ubiquitous expression of OPN afforded increased proliferation to clones in the central tumour region and a decreased variation in clone sizes. Functionally, OPN overexpression also resulted in increased Ki67 positivity in the central tumour regions that was not associated with a change in CAF distribution throughout the tumour (Fig. 1b) .
Using the stochastic clone system, the authors determined that chemotherapy with a combination of oxaliplatin and 5-fluorouracil suppressed the rate of tumour growth, but did not impact fundamental tumour growth dynamics. Treated tumours contained a higher proportion of cells expressing stem-cell markers, such as Lgr5, but nevertheless retained a surface growth dynamic. These analyses provide evidence that even though stem-cell markers are increased during chemotherapeutic intervention, the default of surface tumour growth is unperturbed. This surface growth characteristic is dictated by microenvironmental influences that are not targeted by current chemotherapeutics.
The authors provide compelling evidence that challenges the promise of directly targeting CSCs in primary CRC. This observation is partially supported by previous work demonstrating that Lgr5 + cells have an enhanced ability to establish tumours in the liver and subcutaneous environments, but are not required for primary tumour survival 5 . Combining these data with those of the current study advocates that the ability of a cell to establish a tumour and to drive tumour growth should be considered as independent cellular traits. Furthermore, an important follow-up Zhang et al. started by identifying genes that are transcriptionally regulated by BAP1-dependent H2A-Ub occupancies, using an elegant combination of transcriptomics, epigenomic analyses and cancer genomics. In the UMRC6 cell line that has low levels of BAP1, they expressed an active or inactive, mutated form of BAP1, followed by chromatin immunoprecipitation sequencing (ChIPseq) to compare the genome-wide occupancies of H2A-Ub. This revealed that BAP1 decreased H2A-Ub occupancies for more than 5,000 genes. In parallel, they used RNA-sequencing to identify genes whose expression was changed in response to BAP1 activity. Combining the two data sets led to a manageable set of genes that fitted the expected pattern of lower expression when BAP1 deubiquitinated the associated H2A. To pinpoint the candidate genes associated with cancer, the authors analysed BAP1 levels, gene expression profiles and patient survival in a Cancer Genome Atlas (TCGA) kidney clear cell carcinoma (KIRC) data set compared with that of normal cells, and identified SLC7A11, which was prominently downregulated in response to BAP1 expression (Fig. 1) . SLC7A11 was also among the top hits identified in the RNA-sequencing and ChIP-seq analysis of UMRC6 cells. This finding is in line with a recent study reporting that p53 activates ferroptosis by suppressing the expression of SLC7A11 (ref. 8 ), implicating SLC7A11 as a promising candidate gene responsible for tumour suppression by BAP1. The authors further showed that BAP1 expression was inversely correlated with that of SLC7A11 in KIRC and other types of cancer. In addition, re-expression of active BAP1, but not of its inactive, mutant form, in BAP1-deficient cells decreased H2A-Ub occupancy of the SLC7A11 promoter and gene region, and reduced SLC7A11 expression. Together, these data indicate that BAP1 acts as a tumour suppressor by decreasing SLC7A11 expression to enhance cell death.
SLC7A11 is a cystine-glutamate exchanger that takes up cystine into the cell 9 . Cystine is critical for glutathione (GSH) synthesis, a major component of the cell's antioxidant defences. Crucially, downregulating expression of SLC7A11, or inhibiting its activity with erastin, leads to cell death by ferroptosis 3, 4 . Ferroptosis occurs when free iron induces lipid peroxidation, and therefore inhibition of glutathione peroxidase 4 (GPX4) (which degrades the lipid hydroperoxides generated
